Year Founded
2021
Ownership
Private
Employees
~10
Stage
Phase 2
Modalities
Small interfering RNA (siRNA)RNA interference (RNAi)

Argo Biopharma General Information

Multiple programs in clinical development, with BW-01 in Phase 2 for severe hypertriglyceridemia and BW-03 in Phase 1 for CHB. Completed Phase 1 trials for BW-01 in China and Australia.

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

BW-01
Phase 2
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Argo Biopharma's pipeline data

Book a demo

Key Partnerships

Novartis

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Argo Biopharma Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Argo Biopharma's complete valuation and funding history, request access »

Argo Biopharma Investors

CS Capital (lead)
Investor Type: Venture Capital
Holding: Minority
HUAGAI Capital
Investor Type: Venture Capital
Holding: Minority
ONEHEALTH&HAIHE Capital
Investor Type: Venture Capital
Holding: Minority
Investor Name
Investor Type
Holding
Investor Name
Investor Type
Holding
You're viewing 3 of 4 investors. Get the full list »